188 related articles for article (PubMed ID: 35499388)
1. Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
Deng S; Krutilina RI; Hartman KL; Chen H; Parke DN; Wang R; Mahmud F; Ma D; Lukka PB; Meibohm B; Seagroves TN; Miller DD; Li W
Mol Cancer Ther; 2022 Jul; 21(7):1103-1114. PubMed ID: 35499388
[TBL] [Abstract][Full Text] [Related]
2. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
[TBL] [Abstract][Full Text] [Related]
3. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
[TBL] [Abstract][Full Text] [Related]
4. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities.
Song J; Wang SY; Wang X; Jia MQ; Tian XY; Fu XJ; Jin CY; Zhang SY
Bioorg Chem; 2023 Aug; 137():106580. PubMed ID: 37149948
[TBL] [Abstract][Full Text] [Related]
6. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
Mahmud F; Deng S; Chen H; Miller DD; Li W
Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
[TBL] [Abstract][Full Text] [Related]
7. G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly.
Lv X; He C; Huang C; Hua G; Wang Z; Remmenga SW; Rodabough KJ; Karpf AR; Dong J; Davis JS; Wang C
Mol Cancer Ther; 2017 Jun; 16(6):1080-1091. PubMed ID: 28258163
[TBL] [Abstract][Full Text] [Related]
8. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
9. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.
Lin S; Du T; Zhang J; Wu D; Tian H; Zhang K; Jiang L; Lu D; Sheng L; Li Y; Ji M; Chen X; Xu H
J Med Chem; 2022 Dec; 65(24):16372-16391. PubMed ID: 36511661
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities.
Li G; Wang Y; Li L; Ren Y; Deng X; Liu J; Wang W; Luo M; Liu S; Chen J
Eur J Med Chem; 2020 Sep; 202():112519. PubMed ID: 32650183
[TBL] [Abstract][Full Text] [Related]
12. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
[TBL] [Abstract][Full Text] [Related]
13. A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non-small cell lung cancers.
Liu Z; Huang L; Zhou T; Chang X; Yang Y; Shi Y; Hao M; Li Z; Wu Y; Guan Q; Zhang W; Zuo D
J Biol Chem; 2022 Jul; 298(7):102063. PubMed ID: 35618020
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
[TBL] [Abstract][Full Text] [Related]
15. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Spirocyclohexadienones as New Anti-Migratory Compounds in Triple- Negative Breast Cancer Cell Migration.
Altei WF; Pachane BC; Martins LJ; Gomes RC; Santos RN; Fernandes DC; Selistre-de-Araújo HS; Coelho F; Andricopulo AD
Anticancer Agents Med Chem; 2021; 21(14):1901-1910. PubMed ID: 33292143
[TBL] [Abstract][Full Text] [Related]
17. pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma.
Bhattarai RS; Bariwal J; Kumar V; Hao C; Deng S; Li W; Mahato RI
J Control Release; 2022 Oct; 350():569-583. PubMed ID: 36037976
[TBL] [Abstract][Full Text] [Related]
18. Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis.
Krutilina RI; Hartman KL; Oluwalana D; Playa HC; Parke DN; Chen H; Miller DD; Li W; Seagroves TN
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358755
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
20. Laxiflorin B covalently binds the tubulin colchicine-binding site to inhibit triple negative breast cancer proliferation and induce apoptosis.
Yang H; Zhang T; Chen C; Chiang C; Chen K; Wu Y; Liu Z; Zhou Y; Zhu L; Zheng D
Chem Biol Interact; 2023 Sep; 383():110681. PubMed ID: 37648048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
